Committed to advancing
medical breakthroughs
Learn how HM1 donates 1.5% of its NTA annually to leading medical research institutes, driving innovation and life-saving discoveries.
Hearts & Minds is dedicated to supporting leading Australian medical research organisations through our Listed Investment Company, HM1 and our annual event, Sohn Hearts & Minds.
Our philanthropic mission is achieved by waiving traditional management and performance fees and instead donating an amount equal to 1.5% of HM1's Net Tangible Assets (NTA) each year. This commitment is further amplified by the pro bono contributions of our fund managers, key service providers and the fundraising efforts of Sohn Hearts & Minds.
HM1 makes donations to nominated beneficiaries every six months, based on the average monthly NTA for the prior half-year. Hearts & Minds is one of Australia’s Top 30 Corporate Philanthropists, and to date has donated over $78 million to medical research.
Why support medical research?
Investment in medical research leads directly to the development of groundbreaking treatments, as well as significant economic returns. Here’s why it matters:
Every person in Australia has benefited from medical research, which leads to the development of new drugs, vaccines, and procedures that prevent or treat diseases.
Australia is a global leader in medical research. Australian scientists have made some of the world’s most important and life-changing medical discoveries. Australia’s health and medical research is an outperforming sector – health science research in Australia is ranked 7th globally, and Australia is ranked 5th in the World Index of Healthcare Innovation (Springer Nature, 2023).
Medical research offers an impressive return on investment. It's estimated that investment in Australian medical research has returned a net benefit of $78 billion. On average, every dollar invested in medical research returns $3.90 in benefits to the population. (Association of Australian Medical Research Institutes, 2018).
In 2022, Australia produced 3.4% of the world’s published research, despite being only 0.33% of the world’s population (Australian Universities Accord, 2024).
How are beneficiaries nominated?
We are agnostic in our pursuit of unlocking the boldest medical research ideas. As a result, we support a wide range of research focused on diagnosing, treating, and ultimately finding a cure for various diseases.
Beneficiaries are nominated by the HM1 Board and Core Fund Managers.
All nominated beneficiaries are subject to our selection criteria and due diligence reviews to ensure we are maximising our impact.
to beneficiaries
nominated by our seven
Core Fund Managers.
We are grateful for the ongoing contributions of our Core Fund Managers, Board, and key stakeholders, whose pro bono commitment ensures Hearts & Minds can continue driving impactful medical research.
